@entity63 ( @entity63 ) is a powerful cardioprotective cellular mechanism that has been related to the "warm-up phenomenon" or "walk-through" angina, and has been documented through the use of sequential exercise tests (ETs). It is known that several drugs, for example, cromokalim, @entity1706 , @entity859 , and @entity7976 , can interfere with the cellular pathways of @entity63 . The purpose of this article is to report the effect of the anti- @entity63 agent @entity1481 ( @entity2904 ) on @entity63 in symptomatic @entity453 ( @entity453 ) @entity1 .We conducted a prospective study evaluating @entity63 by the analysis of @entity63 parameters in 2 sequential ETs. In phase I, without @entity2904 , @entity1 underwent @entity2232 and @entity15577 with a 30-minute interval between them. In phase II, after 1 week of @entity2904 35mg twice daily, all @entity1 underwent 2 consecutive ETs ( @entity6423 and ET4). @entity63 was considered present when the time to 1.0-mm segment ST on electrocardiogram deviation (T-1.0mm) and rate pressure product (RPP) were greater in the second of 2 tests. The improvement in T-1.0mm and RPP were compared in the 2 phases: without @entity2904 and after 1-week @entity2904 to assess the action of such drug in myocardial protective mechanisms. ETs were analyzed by 2 independent cardiologists.From 135 @entity453 @entity1 screened, 96 met inclusion criteria and 62 completed the study protocol. Forty @entity1 manifested @entity63 by demonstrating an improvement in T-1.0mm in @entity15577 compared with @entity2232 , without the use of any drugs (phase I). In phase II, after 1-week @entity2904 , 26 @entity1 (65%) did not show any incremental result in @entity63 parameters in ET4 compared with @entity6423 . Furthermore, of these @entity1 , 8 (20%) had @entity63 blockage.In this study, @entity2904 did not add any benefit to @entity63 in @entity1 with stable symptomatic @entity453 .

Role of XXXX in Ischemic Preconditioning in @entity1 With Symptomatic @entity453 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity859 :: ('MESH:D000241', 'Chemical') :: ['adenosine'] @entity63 :: ('MESH:D007511', 'Disease') :: ['Ischemic preconditioning', 'IP', 'ischemic'] @entity2232 :: ('1906', 'Gene') :: ['ET1'] @entity15577 :: ('1907', 'Gene') :: ['ET2'] @entity1481 :: ('MESH:D014292', 'Chemical') :: ['trimetazidine'] @entity6423 :: ('1908', 'Gene') :: ['ET3'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ'] @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease'] @entity7976 :: ('MESH:D020108', 'Chemical') :: ['nicorandil'] @entity1706 :: ('MESH:D020110', 'Chemical') :: ['pinacidil']
@entity1481 :: (MESH:D014292,Chemical) :: ['Trimetazidine']
